Pharma and healthcare's digital ad spend to reach $10B next year: report

Digital marketing word cloud
Data, analytics and targeted TV are fueling the swell of digital advertising in pharma and healthcare, says programmatic firm PulsePoint. (Pixabay)

Digital advertising is booming in pharma and healthcare, and it's expected to rise to $10 billion in 2020. That’s according to a new report from PulsePoint, and it represents a 13% increase over current spending.

Healthcare advertising currently only accounts for about 2% of total digital advertising spending in the U.S. However, advertising is not only growing in spending from the marketer side, but also in interest from consumers. The report found that consumers engage with health content for longer periods of time than with content from other industries including news, finance and even travel.

RELATED: Practical magic: Google counsels pharma to create 'seamless' digital experiences

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

One of the keys to pharma and healthcare digital growth is programmatic advertising, which integrates data, automation, insights and technology in real time, Chris Neuner, chief revenue officer at PulsePoint, said.

In pharma and healthcare, for instance, PulsePoint found that three out of four people were most likely to engage with health advertising when it offered additional information. Another two out of three would respond to “relevant informative content.”

“As marketers are thinking about television, digital and social, they’re saying, 'if I can use data in a real-time capacity and target the user to increase my chances of having the right communication with that patient or physician, why don’t I do that?'” Neuner said.

And yes, he did include television in his vision for the future of programmatic pharma advertising. Connected TV, addressable TV and over-the-top viewing—services such as DirecTV, Netflix, Hulu and YouTube, which all use some kind of internet-connected TV viewing—allow marketers to reach individual consumers using data and analytics.

RELATED: Tipping point? Digital communications from pharma finally get their due with doctors

“TV advertising isn’t over, it’s advancing,” he said. “Being able to pull data from multiple sources—purchase behavior, website activity, browsing behavior, medical claims data, for instance—can build an audience, in a HIPAA-compliant way, and allow us to build propensity. We can then create a device into the television that can target people specifically who have a propensity to that product.”

The result is continued traditional pharma channel TV advertising, but combined with consumer data and applied analytics to reach interested consumers, which should result in more efficient and effective media spending.

Suggested Articles

New models are needed to assess the value of gene and cell therapies and provide reimbursement, Novartis CEO Vas Narasimhan says.

With stocks tumbling and a price-fixing lawsuit hanging over its head, Mylan’s future is looking spooky. Could a new acquisition help turn the tide?

AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch,…